newsfilter
← Latest News
GlobeNewswire·

NeOnc Is Putting Two Brain Cancer Programs on the Global Stage

  • NeOnc Technologies Holdings (NASDAQ: NTHI) announced that data from its intranasal NEO100 & oral NEO212 programs will be presented at the Society for Neuro-Oncology Annual Meeting on November 13, 2026.
  • The company plans to advance a clinical strategy targeting approximately 500 patients across 30 hospitals in three countries.
  • Presentation 1 covers updated results for NEO100 in recurrent WHO Grade III/IV IDH1-mutant astrocytoma, combining Phase 1/2a study data with compassionate use experience.
  • Presentation 2 covers Phase 1 safety, pharmacokinetics, & early activity signals for NEO212 in temozolomide-resistant recurrent glioblastoma & brain metastases.
  • NEO100 utilizes a non-invasive intranasal delivery approach to bypass the blood-brain barrier using highly purified perillyl alcohol.
  • NEO212 is an investigational oral conjugate of temozolomide & NEO100 that has completed Phase 1 dose escalation & is advancing toward Phase 2 development.
  • The company utilizes patented 3D bioprinting technology & artificial intelligence to create patient-derived tumor models for precision medicine.
  • NeOnc has expanded its international footprint with the appointment of Ali Alabedin to its board & developments in Abu Dhabi.
  • Technical analysis indicates a potential short squeeze scenario with approximately 877,000 shares reported short as of mid-October.
  • Roth Capital analyst Jonathan Aschoff initiated coverage with a Buy rating & a $20 price target, projecting commercial launches in 2029 & 2030.
  • The press release is a paid editorial disclosure from 24/7 Market News & contains forward-looking statements subject to significant risks.